Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allergan

The groups are worried about reduced competition if the merger goes through.

17 Consumer Groups and Unions Ask FTC to Block AbbVie's Acquisition of Allergan

A group of unions and consumer groups wrote to U.S. antitrust enforcers on Tuesday to oppose a proposed remedy that could lead to U.S.

Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan

Eli Lilly

Which of these top dividend growth stocks is the more attractive buy right now?

Better Buy: AbbVie vs.  Eli Lilly

Gilead Sciences

Promising pipelines. Attractive valuations.

Better Buy: AbbVie vs.  Gilead Sciences

Bristol-Myers

These businesses have the winning trifecta: a stable dividend, ongoing earnings growth, and attractive valuation.

3 High-Yielding U.S. Pharmaceutical Companies to Consider

There's more to the big drugmaker's story than just Humira.

3 Reasons AbbVie Is a Better Bargain Than You Might Think

Shares of pharmaceutical companies often trade based upon prospects for growth in future years.

Buy AbbVie for its Growth Prospects, Yield and Low Valuation

AbbVie reported fourth-quarter results that topped expectations. Its valuation discount is no longer warranted.

AbbVie Is a Dividend Growth Stock at a Bargain Price

AbbVie: $100 Next

Despite Humira's declining international sales, AbbVie is still worth considering.

With Solid Fourth Quarter Results, AbbVie Shows That Its Growth Days Are Far From Over

Pfizer

Which of these highly coveted dividend stocks is the choice right now?

Better Buy: Pfizer vs. AbbVie

AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

AbbVie Is Nearing Takeover Of Allergan — Is It Time To Add AbbVie Stock?

The big drugmaker didn't just beat Wall Street estimates in Q4. It provided better-than-expected 2020 guidance, too.

Here's How AbbVie Impressed Investors With Its Q4 Update

AbbVie (ABBV) beat on earnings in the fourth quarter of 2019 while revenues meet the same. Shares up in pre-market trading following a solid 2020 outlook.

AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up

AbbVie (ABBV) earnings for the biopharmaceutical company's fourth quarter of 2019 have ABBV stock heading higher on Friday.
The post AbbVie Earnings: ABBV Stock Jumps 6% on Q4 Beats appeared first on InvestorPlace.

AbbVie Earnings: ABBV Stock Jumps 6% on Q4 Beats

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q4 2019 Results - Earnings Call Transcript

Better than expected performances from new drugs and Humira gave investors plenty to look forward to in 2020.

AbbVie Reports Estimate-Beating Fourth-Quarter Earnings Results

AbbVie Inc  on Friday forecast full-year earnings well above Wall Street estimates, as the U.S. drugmaker looks to new treatments and its pending acquisition of Allergan Plc  to drive growth beyond 2023, when its cash cow Humira loses patent protection.

New drugs contribute to AbbVie's upbeat 2020 view; shares hit year-high

When AbbVie Inc. (NYSE: ABBV) released its fourth-quarter financial results before the markets opened on Friday, the pharmaceutical giant said that it had $2.21 in earnings per share (EPS) and $8.7 billion in revenue.

AbbVie Wows Again With Q4 Results

AbbVie (ABBV) delivered earnings and revenue surprises of 0.45% and 0.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q4 Earnings and Revenues Beat Estimates

AbbVie (NYSE: ABBV) shares are trading higher on Friday after the company reported better-than-expected fourth-quarter EPS and sales results.

AbbVie Reports Q4 Earnings Beat

Shares of AbbVie Inc. ABBV, +0.63% climbed 2% in premarket trading on Friday although the drugmaker beat earnings expectations for the quarter.

AbbVie's stock rises on strong earnings

AbbVie narrowly topped Q4 earnings views while guiding higher for 2020. Shares of the drug giant rose early Friday, moving toward a buy point.

AbbVie Earnings Top, Guidance Solid; Drug Giant Rises Toward Buy Point

AbbVie Inc  on Friday forecast 2020 earnings above Wall Street estimates as the drugmaker expects growth to be powered by its new treatments for psoriasis and rheumatoid arthritis at a time when sales of its blockbuster drug Humira slow.

AbbVie leans on new treatments to forecast upbeat 2020 profit

On Friday, February 7, AbbVie (NYSE: ABBV) will report its last quarter's earnings.

News for AbbVie Stock (ABBV)